상단으로
Choose your location
Select your country or region to view content specific to your country.
Choose your country
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in each country.
Seegene to Present at 34th annual J.P. Morgan Healthcare Conference
Jan 14, 2016
?
Seegene Inc. (096530.KQ) announced today that it has been invited to present the Company’s innovative molecular technologies at the 34th J.P. Morgan Healthcare Conference on Wednesday, 13th January, 2016 at 1:30 PM PST in at the Westin St. Francis Hotel in San Francisco.
?
The annual J.P. Morgan Healthcare Conference is the most prestigious and largest healthcare investment conference, where Seegene has been presented for the last three years.
?
Dr. Jong-Yoon Chun, Founder and CEO of Seegene, will emphasize on recent corporate developments and next steps which convey the company’s business strategies of expansion of MDx product portfolio and increase of alliances with global companies.
?
Allplex™ Assays based on MuDT™(Multiple Detection Temperatures) PCR Technology, Seegene’s newly launched products, have been successfully recognized in the global IVD(In-Vitro Diagnostic) market. Furthermore, the superiority of Seegene’s technologies is rapidly endorsed by entering into major co-development agreements with leading global diagnostics companies, such as Beckman Coulter, Qiagen, and BD.
?
?“Seegene is competitively positioned in the market. Our unique multiplex PCR technologies have enabled us to continually develop impactful and diverse products for medical diagnosis. We believe that it will also provide us with opportunities to expand our molecular diagnostics market share through more strategic alliances with global companies,” Said Dr. Jong-Yoon Chun, Seegene’s Founder and CEO.